Summary

The Global Osteoporosis Market was valued at USD 14,956.06 million in 2025 and is projected to reach USD 28,335.59 million by 2035. The market is anticipated to expand at a CAGR of 6.51% during the forecast period, driven by the rising aging population and increasing prevalence of bone-related disorders worldwide.

Rising Awareness of Postmenopausal Bone Health
One of the key reasons fueling global osteoporosis market is women becoming aware of their risk of bone loss post menopause as a result of which a major campaign, health screening and early diagnosis program are being rolled out globally to adopt more preventive treatment and therapy for the disease.

Segment-Wise Market Overview
By Drug Class
- Branded: Premium therapies with strong physician preference.
- Generic: Cost-effective treatments driving wider patient access.
By Type
- Bisphosphonates: Widely prescribed for preventing bone density loss.
- Parathyroid Hormone Therapy: Stimulates new bone formation effectively.
- RANK Ligand (RANKL) Inhibitors: Reduces bone resorption and fracture risks.
- Selective Oestrogen Receptor Modulators (SERMs): Supports bone health in postmenopausal women.
- Calcitonin: Helps regulate calcium and reduce bone loss.
- Sclerostin Inhibitors: Promotes rapid bone formation and strength.
- Others: Emerging therapies expanding osteoporosis treatment possibilities.
By Route of Administration
- Oral: Convenient option for long-term osteoporosis management.
- Injectable: Preferred for severe and advanced osteoporosis cases.
- Others: Alternative delivery methods improving treatment flexibility.
By Application
- Primary Osteoporosis: Most common age-related bone disorder segment.
- Secondary Osteoporosis: Linked with underlying diseases or medications.
- Others: Includes rare and condition-specific osteoporosis cases.
By Gender
- Male: Rising awareness increasing diagnosis among aging men.
- Female: Largest patient population due to menopause-related risks.
By Mechanism Action
- Antiresorptive: Slows bone breakdown and mineral loss effectively.
- Anabolic: Encourages bone growth and density improvement.
By Distribution Channel
- Retail Pharmacies: Major source for routine osteoporosis medications.
- Hospital Pharmacies: Essential for advanced therapy distribution and monitoring.
- Online: Growing digital access improving medication convenience.

While North America leads the osteoporosis market worldwide owing to well-developed healthcare system, large aging population, and high level of bone health awareness, Europe continues to show considerable growth mainly due to an increase in fragility fracture cases and a growing elderly population. The Asia-Pacific region is the fastest-growing market on account of rapid urbanization, enhanced healthcare facilities, and an increase in the healthcare expenditure of the middle class, whereas South America and the Middle East & Africa are likely to grow steadily through healthcare modernization and economic diversification activities.

Strategic Biosimilar Expansion
In June 2025, Sandoz Group AG augmented its osteoporosis lineup by launching WYOST and Jubbonti, the first FDA-approved interchangeable denosumab biosimilars in the U.S. The launch enables more people suffering from osteoporosis and cancer-related skeletal complications to get affordable treatment.

Advanced Treatment Potential
Sclerostin inhibitors are disrupting the osteoporosis market with their immense possibilities as they can treat high-risk patients with severe bone loss and history of fractures efficiently. These drugs simultaneously stimulate bone formation and reduce bone resorption that makes them highly effective as compared to traditional anabolic therapies.

Key Report Attributes
- Market Size 2025: USD 14,956.06 Million
- Market Size 2035: USD 28,335.59 Million
- CAGR (2025-2035): 6.51%
- Base Year: 2024
- Market Forecast Period: 2025-2035

Industry Segmentations Growth
- By Drug Class: Branded - 6.08%, Generic - 7.13%.
- By Type: Bisphosphonates - 7.01%, Parathyroid Hormone Therapy - 6.52%.
- By Route of Administration: Oral - 5.98%, Injectable - 6.71%.
- By Application: Primary Osteoporosis - 6.70%, Secondary Osteoporosis - 5.49%.
- By Gender: Male - 4.88%, Female - 7.06%.
- By Mechanism Action: Antiresorptive - 6.90%, Anabolic - 5.53%.
- By Distribution Channel: Retail Pharmacies - 6.73%, Hospital Pharmacies - 5.85%.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ........................................... 22
1.1 Overview .......................................... 22
1.2 MARKET ATTRACTIVENESS ANALYSIS ..................................... 23
1.3 GLOBAL OSTEOPOROSIS MARKET, BY DRUG CLASS................ 24
1.4 GLOBAL OSTEOPOROSIS MARKET, BY TYPE ............................ 25
1.5 GLOBAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION ................................. 26
1.6 GLOBAL OSTEOPOROSIS MARKET, BY APPLICATION .............. 27
1.7 GLOBAL OSTEOPOROSIS MARKET, BY GENDER ....................... 28
1.8 GLOBAL OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION ....................................... 29
1.9 GLOBAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL ....................................... 30
1.10 GLOBAL OSTEOPOROSIS MARKET, BY REGION ........................ 31
2 MARKET INTRODUCTION ....................................... 33
2.1 DEFINITION ..................................... 33
2.2 SCOPE OF THE STUDY .................... 33
2.3 Research Objective ......................... 33
2.4 MARKET STRUCTURE ..................... 34
3 RESEARCH METHODOLOGY ................................. 35
3.1 Overview .......................................... 35
3.2 DATA flow ....................................... 37
3.2.1 DATA MINING PROCESS ........ 37
3.3 Purchased Database: ...................... 38
3.4 Secondary Sources: ........................ 39
3.4.1 SECONDARY RESEARCH DATA FLOW: ............................. 40
3.5 Primary Research: ........................... 41
3.5.1 PRIMARY RESEARCH DATA FLOW: .................................. 42
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED................................. 43
3.6 Approaches for market size estimation: .................................... 44
3.6.1 REVENUE ANALYSIS APPROACH ...................................... 44
3.7 Data forecasting .............................. 45
3.7.1 DATA FORECASTING TYPE ............................................... 45
3.8 Data modeling ................................. 46
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ............................ 46
3.8.2 DATA MODELING: ................... 47
3.9 Teams and Analyst Contribution ..... 49
4 MARKET DYNAMICS ............................................... 51
4.1 INTRODUCTION ............................... 51
4.2 Drivers ............................................. 52
4.2.1 AGING GLOBAL DEMOGRAPHICS ..................................... 52
4.2.2 TRANSITION TO HIGH-EFFICACY BIOLOGICS .................. 52
4.2.3 INCREASED POSTMENOPAUSAL AWARENESS ................ 53
4.2.4 ADVANCEMENTS IN INJECTABLE FORMULATIONS ........ 53
4.3 Restraints ........................................ 54
4.3.1 SIDE EFFECTS AND SAFETY CONCERNS ......................... 54
4.3.2 POOR MEDICATION ADHERENCE ..................................... 55
4.3.3 PATENT EXPIRY AND GENERIC PRICE PRESSURE ........... 55
4.4 Opportunities ................................... 56
4.4.1 GROWTH IN SCLEROSTIN INHIBITORS ............................ 56
4.4.2 DEVELOPMENT OF NOVEL MECHANISM-BASED THERAPIES .................................... 57
5 MARKET FACTOR ANALYSIS ................................. 58
5.1 Regulatory Environment & Compliance ...................................... 58
5.2 Technological Trends & Innovation ............................................ 59
5.3 Patient Demographics & Disease Burdens ................................. 60
5.4 Pricing Analysis & Reimbursement Dynamics ........................... 60
5.4.1 PRICING ANALYSIS ................ 60
5.4.2 REIMBURSEMENT DYNAMICS .......................................... 61
5.5 Market Entry & Exit Barriers ............ 62
5.5.1 BARRIERS TO ENTRY ............. 62
5.5.2 BARRIERS TO EXIT ................. 62
5.6 Partnerships & Collaborations ........ 63
5.7 Consumer & Healthcare Provider Preferences .......................... 64
5.7.1 CONSUMER PREFERENCES .............................................. 64
5.7.2 HEALTHCARE PROVIDER PREFERENCES ......................... 64
5.8 PESTLE ANALYSIS .......................... 65
5.8.1 POLITICAL FACTORS ............. 65
5.8.2 ECONOMIC FACTORS ............ 65
5.8.3 SOCIAL FACTORS ................... 65
5.8.4 TECHNOLOGICAL FACTORS ............................................. 66
5.8.5 LEGAL FACTORS .................... 66
5.8.6 ENVIRONMENTAL FACTORS ............................................ 66
5.9 Porter's Five Forces Model.............. 67
5.9.1 THREAT OF NEW ENTRANTS ............................................ 67
5.9.2 BARGAINING POWER OF SUPPLIERS ............................... 68
5.9.3 THREAT OF SUBSTITUTES ..... 68
5.9.4 BARGAINING POWER OF BUYERS .................................... 68
5.9.5 INTENSITY OF RIVALRY ......... 68
5.10 Product Pipeline Analysis ................ 69
5.11 Case Study Analysis ........................ 69
5.12 Investment & Funding Scenarios ............................................... 70
5.13 Post-Market Surveillance & Safety Data..................................... 70
5.14 disease overview ............................. 71
5.15 diagnosis ......................................... 72
5.16 CURRENT TREATMENT .................. 73
6 GLOBAL OSTEOPOROSIS MARKET, BY DRUG CLASS ................................. 76
6.1 Overview .......................................... 76
7 GLOBAL OSTEOPOROSIS MARKET, BY TYPE ..... 78
7.1 Overview .......................................... 78
8 GLOBAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION ...... 81
8.1 Overview .......................................... 81
9 GLOBAL OSTEOPOROSIS MARKET, BY APPLICATION ................................. 83
9.1 Overview .......................................... 83
10 GLOBAL OSTEOPOROSIS MARKET, BY GENDER ......................................... 85
10.1 Overview .......................................... 85
11 GLOBAL OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION .............. 87
11.1 Overview .......................................... 87
12 GLOBAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL ............. 89
12.1 Overview .......................................... 89
13 GLOBAL OSTEOPOROSIS MARKET, BY REGION ........................................... 91
13.1 Overview .......................................... 91
13.2 NORTH AMERICA ............................ 92
13.2.1 US ........................................... 97
13.2.2 CANADA ................................. 100
13.3 EUROPE ........................................... 103
13.3.1 GERMANY ............................... 108
13.3.2 UK ........................................... 111
13.3.3 FRANCE .................................. 114
13.3.4 NETHERLANDS ...................... 117
13.3.5 ITALY ...................................... 120
13.3.6 SPAIN ..................................... 123
13.3.7 REST OF EUROPE ................... 126
13.4 asia-pacific ...................................... 129
13.4.1 CHINA ..................................... 135
13.4.2 INDIA ...................................... 138
13.4.3 JAPAN .................................... 141
13.4.4 SOUTH KOREA ....................... 144
13.4.5 MALAYSIA .............................. 147
13.4.6 THAILAND .............................. 150
13.4.7 INDONESIA ............................. 153
13.4.8 REST OF ASIA-PACIFIC .......... 156
13.5 LATIN AMERICA .............................. 159
13.5.1 BRAZIL .................................... 164
13.5.2 MEXICO .................................. 167
13.5.3 ARGENTINA ............................ 170
13.5.4 REST OF LATIN AMERICA ...... 173
13.6 middle east & africa ........................ 176
13.6.1 GCC COUNTRIES .................... 181
13.6.2 SOUTH AFRICA ....................... 184
13.6.3 REST OF MIDDLE EAST & AFRICA ..................................... 187
14 COMPETITIVE LANDSCAPE ................................... 191
14.1 Introduction ..................................... 191
14.2 Market Share Analysis, 2025 ........... 191
14.3 competitor dashboard ..................... 192
14.4 Public Players Stock Summary ....... 193
14.5 Comparative Analysis: Key Players Financial ............................ 193
14.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ....................... 194
14.6.1 PRODUCT LAUNCH ................ 194
14.6.2 CLINICAL STUDY .................... 194
14.6.3 RELAUNCH ............................. 194
14.6.4 REGULATORY APPROVAL ...... 195
14.6.5 PARTNERSHIP ........................ 195
15 COMPANY PROFILES ............................................. 196
15.1 Amgen Inc. ...................................... 196
15.1.1 COMPANY OVERVIEW ............ 196
15.1.2 FINANCIAL OVERVIEW ........... 197
15.1.3 PRODUCTS OFFERED ............. 197
15.1.4 KEY DEVELOPMENTS ............. 198
15.1.5 SWOT ANALYSIS .................... 198
15.1.6 KEY STRATEGIES ................... 198
15.2 Pfizer Inc. ........................................ 199
15.2.1 COMPANY OVERVIEW ............ 199
15.2.2 FINANCIAL OVERVIEW ........... 200
15.2.3 PRODUCTS OFFERED ............. 201
15.2.4 KEY DEVELOPMENTS ............. 201
15.2.5 SWOT ANALYSIS .................... 202
15.2.6 KEY STRATEGIES ................... 202
15.3 SANDOZ GROUP AG ........................ 203
15.3.1 COMPANY OVERVIEW ............ 203
15.3.2 FINANCIAL OVERVIEW ........... 204
15.3.3 PRODUCTS OFFERED ............. 204
15.3.4 KEY DEVELOPMENTS ............. 205
15.3.5 KEY STRATEGIES ................... 205
15.4 NOVARTIS AG.................................. 206
15.4.1 COMPANY OVERVIEW ............ 206
15.4.2 FINANCIAL OVERVIEW ........... 207
15.4.3 PRODUCTS OFFERED ............. 208
15.4.4 KEY DEVELOPMENTS ............. 208
15.4.5 KEY STRATEGIES ................... 208
15.5 Eli Lilly and Company ...................... 209
15.5.1 COMPANY OVERVIEW ............ 209
15.5.2 FINANCIAL OVERVIEW ........... 210
15.5.3 PRODUCTS OFFERED ............. 211
15.5.4 KEY DEVELOPMENTS ............. 211
15.5.5 KEY STRATEGIES ................... 211
15.6 Teva Pharmaceutical Industries Ltd. ......................................... 212
15.6.1 COMPANY OVERVIEW ............ 212
15.6.2 FINANCIAL OVERVIEW ........... 213
15.6.3 PRODUCTS OFFERED ............. 214
15.6.4 KEY DEVELOPMENTS ............. 214
15.6.5 KEY STRATEGIES ................... 214
15.7 AbbVie Inc. ...................................... 215
15.7.1 COMPANY OVERVIEW ............ 215
15.7.2 FINANCIAL OVERVIEW ........... 215
15.7.3 PRODUCTS OFFERED ............. 217
15.7.4 KEY DEVELOPMENTS ............. 217
15.7.5 SWOT ANALYSIS .................... 217
15.7.6 KEY STRATEGIES ................... 218
15.8 Radius Health, Inc. .......................... 219
15.8.1 COMPANY OVERVIEW ............ 219
15.8.2 FINANCIAL OVERVIEW ........... 220
15.8.3 PRODUCTS OFFERED ............. 220
15.8.4 KEY DEVELOPMENTS ............. 220
15.8.5 SWOT ANALYSIS .................... 221
15.8.6 KEY STRATEGIES ................... 222
15.9 CIPLA ............................................... 223
15.9.1 COMPANY OVERVIEW ............ 223
15.9.2 FINANCIAL OVERVIEW ........... 224
15.9.3 PRODUCTS OFFERED ............. 225
15.9.4 KEY DEVELOPMENTS ............. 225
15.9.5 SWOT ANALYSIS .................... 225
15.9.6 KEY STRATEGIES ................... 226
15.10 Organon ........................................... 227
15.10.1 COMPANY OVERVIEW ............ 227
15.10.2 FINANCIAL OVERVIEW ........... 228
15.10.3 PRODUCTS OFFERED ............. 229
15.10.4 KEY DEVELOPMENTS ............. 229
15.10.5 KEY STRATEGIES ................... 229
16 DATA CITATIONS .......... 230

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 48
TABLE 2 PRODUCT PIPELINE 69
TABLE 3 GLOBAL OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 77
TABLE 4 GLOBAL OSTEOPOROSIS MARKET, BY TYPE, 2019-2035 (USD MILLION) 79
TABLE 5 GLOBAL OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 82
TABLE 6 GLOBAL OSTEOPOROSIS MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 84
TABLE 7 GLOBAL OSTEOPOROSIS MARKET, BY GENDER, 2019-2035 (USD MILLION) 86
TABLE 8 GLOBAL OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD MILLION) 88
TABLE 9 GLOBAL OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 90
TABLE 10 GLOBAL OSTEOPOROSIS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 91
TABLE 11 NORTH AMERICA OSTEOPOROSIS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 93
TABLE 12 NORTH AMERICA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 94
TABLE 13 NORTH AMERICA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 94
TABLE 14 NORTH AMERICA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 95
TABLE 15 NORTH AMERICA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 95
TABLE 16 NORTH AMERICA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 95
TABLE 17 NORTH AMERICA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 96
TABLE 18 NORTH AMERICA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 96
TABLE 19 US: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 97
TABLE 20 US: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 97
TABLE 21 US: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 98
TABLE 22 US: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 98
TABLE 23 US: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 98
TABLE 24 US: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 99
TABLE 25 US: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 99
TABLE 26 CANADA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 100
TABLE 27 CANADA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 100
TABLE 28 CANADA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 101
TABLE 29 CANADA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 101
TABLE 30 CANADA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 101
TABLE 31 CANADA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 102
TABLE 32 CANADA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 102
TABLE 33 EUROPE OSTEOPOROSIS MARKET, BY COUNTRY, 2019-2036 (USD MILLION) 104
TABLE 34 EUROPE: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 105
TABLE 35 EUROPE: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 105
TABLE 36 EUROPE: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 106
TABLE 37 EUROPE: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 106
TABLE 38 EUROPE: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 106
TABLE 39 EUROPE: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 107
TABLE 40 EUROPE: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 107
TABLE 41 GERMANY: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 108
TABLE 42 GERMANY: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 108
TABLE 43 GERMANY: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 109
TABLE 44 GERMANY: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 109
TABLE 45 GERMANY: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 109
TABLE 46 GERMANY: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 110
TABLE 47 GERMANY: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 110
TABLE 48 UK: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 111
TABLE 49 UK: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 111
TABLE 50 UK: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 112
TABLE 51 UK: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 112
TABLE 52 UK: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 112
TABLE 53 UK: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 113
TABLE 54 UK: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 113
TABLE 55 FRANCE: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 114
TABLE 56 FRANCE: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 114
TABLE 57 FRANCE: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 115
TABLE 58 FRANCE: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 115
TABLE 59 FRANCE: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 115
TABLE 60 FRANCE: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 116
TABLE 61 FRANCE: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 116
TABLE 62 NETHERLANDS: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 117
TABLE 63 NETHERLANDS: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 117
TABLE 64 NETHERLANDS: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 118
TABLE 65 NETHERLANDS: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 118
TABLE 66 NETHERLANDS: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 118
TABLE 67 NETHERLANDS: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 119
TABLE 68 NETHERLANDS: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 119
TABLE 69 ITALY: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 120
TABLE 70 ITALY: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 120
TABLE 71 ITALY: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 121
TABLE 72 ITALY: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 121
TABLE 73 ITALY: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 121
TABLE 74 ITALY: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 122
TABLE 75 ITALY: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 122
TABLE 76 SPAIN: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 123
TABLE 77 SPAIN: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 123
TABLE 78 SPAIN: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 124
TABLE 79 SPAIN: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 124
TABLE 80 SPAIN: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 124
TABLE 81 SPAIN: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 125
TABLE 82 SPAIN: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 125
TABLE 83 REST OF EUROPE: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 126
TABLE 84 REST OF EUROPE: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 126
TABLE 85 REST OF EUROPE: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 127
TABLE 86 REST OF EUROPE: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 127
TABLE 87 REST OF EUROPE: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 127
TABLE 88 REST OF EUROPE: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 128
TABLE 89 REST OF EUROPE: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 128
TABLE 90 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 130
TABLE 91 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 131
TABLE 92 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 132
TABLE 93 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 132
TABLE 94 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 133
TABLE 95 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 133
TABLE 96 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 133
TABLE 97 ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 134
TABLE 98 CHINA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 135
TABLE 99 CHINA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 135
TABLE 100 CHINA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 136
TABLE 101 CHINA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 136
TABLE 102 CHINA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 136
TABLE 103 CHINA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 137
TABLE 104 CHINA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 137
TABLE 105 INDIA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 138
TABLE 106 INDIA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 138
TABLE 107 INDIA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 139
TABLE 108 INDIA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 139
TABLE 109 INDIA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 139
TABLE 110 INDIA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 140
TABLE 111 INDIA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 140
TABLE 112 JAPAN: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 141
TABLE 113 JAPAN: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 141
TABLE 114 JAPAN: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 142
TABLE 115 JAPAN: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 142
TABLE 116 JAPAN: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 142
TABLE 117 JAPAN: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 143
TABLE 118 JAPAN: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 143
TABLE 119 SOUTH KOREA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 144
TABLE 120 SOUTH KOREA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 144
TABLE 121 SOUTH KOREA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 145
TABLE 122 SOUTH KOREA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 145
TABLE 123 SOUTH KOREA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 145
TABLE 124 SOUTH KOREA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 146
TABLE 125 SOUTH KOREA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 146
TABLE 126 MALAYSIA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 147
TABLE 127 MALAYSIA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 147
TABLE 128 MALAYSIA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 148
TABLE 129 MALAYSIA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 148
TABLE 130 MALAYSIA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 148
TABLE 131 MALAYSIA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 149
TABLE 132 MALAYSIA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 149
TABLE 133 THAILAND: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 150
TABLE 134 THAILAND: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 150
TABLE 135 THAILAND: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 151
TABLE 136 THAILAND: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 151
TABLE 137 THAILAND: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 151
TABLE 138 THAILAND: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 152
TABLE 139 THAILAND: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 152
TABLE 140 INDONESIA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 153
TABLE 141 INDONESIA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 153
TABLE 142 INDONESIA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 154
TABLE 143 INDONESIA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 154
TABLE 144 INDONESIA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 154
TABLE 145 INDONESIA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 155
TABLE 146 INDONESIA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 155
TABLE 147 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 156
TABLE 148 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 156
TABLE 149 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 157
TABLE 150 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 157
TABLE 151 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 157
TABLE 152 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 158
TABLE 153 REST OF ASIA-PACIFIC: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 158
TABLE 154 LATIN AMERICA: HYALURONIC ACID, BY COUNTRY, 2019-2035 (USD MILLION) 160
TABLE 155 LATIN AMERICA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 161
TABLE 156 LATIN AMERICA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 161
TABLE 157 LATIN AMERICA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 162
TABLE 158 LATIN AMERICA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 162
TABLE 159 LATIN AMERICA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 162
TABLE 160 LATIN AMERICA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 163
TABLE 161 LATIN AMERICA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 163
TABLE 162 BRAZIL: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 164
TABLE 163 BRAZIL: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 164
TABLE 164 BRAZIL: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 165
TABLE 165 BRAZIL: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 165
TABLE 166 BRAZIL: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 165
TABLE 167 BRAZIL: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 166
TABLE 168 BRAZIL: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 166
TABLE 169 MEXICO: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 167
TABLE 170 MEXICO: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 167
TABLE 171 MEXICO: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 168
TABLE 172 MEXICO: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 168
TABLE 173 MEXICO: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 168
TABLE 174 MEXICO: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 169
TABLE 175 MEXICO: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 169
TABLE 176 ARGENTINA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 170
TABLE 177 ARGENTINA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 170
TABLE 178 ARGENTINA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 171
TABLE 179 ARGENTINA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 171
TABLE 180 ARGENTINA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 171
TABLE 181 ARGENTINA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 172
TABLE 182 ARGENTINA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 172
TABLE 183 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 173
TABLE 184 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 173
TABLE 185 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 174
TABLE 186 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 174
TABLE 187 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 174
TABLE 188 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 175
TABLE 189 REST OF LATIN AMERICA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 175
TABLE 190 MIDDLE EAST & AFRICA: HYALURONIC ACID, BY COUNTRY, 2019-2035 (USD MILLION) 177
TABLE 191 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 178
TABLE 192 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 178
TABLE 193 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 179
TABLE 194 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 179
TABLE 195 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 179
TABLE 196 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 180
TABLE 197 MIDDLE EAST & AFRICA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 180
TABLE 198 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 181
TABLE 199 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 181
TABLE 200 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 182
TABLE 201 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 182
TABLE 202 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 182
TABLE 203 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 183
TABLE 204 GCC COUNTRIES: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 183
TABLE 205 SOUTH AFRICA : OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 184
TABLE 206 SOUTH AFRICA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 184
TABLE 207 SOUTH AFRICA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 185
TABLE 208 SOUTH AFRICA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 185
TABLE 209 SOUTH AFRICA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 185
TABLE 210 SOUTH AFRICA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 186
TABLE 211 SOUTH AFRICA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 186
TABLE 212 REST OF MEA: OSTEOPOROSIS MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 187
TABLE 213 REST OF MEA: OSTEOPOROSIS MARKET, BY TYPE, 2019–2035 (USD MILLION) 187
TABLE 214 REST OF MEA: OSTEOPOROSIS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 188
TABLE 215 REST OF MEA: OSTEOPOROSIS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 188
TABLE 216 REST OF MEA: OSTEOPOROSIS MARKET, BY GENDER, 2019–2035 (USD MILLION) 188
TABLE 217 REST OF MEA: OSTEOPOROSIS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD MILLION) 189
TABLE 218 REST OF MEA: OSTEOPOROSIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 189
TABLE 219 PRODUCT LAUNCH 194
TABLE 220 CLINICAL STUDY 194
TABLE 221 RELAUNCH 194
TABLE 222 REGULATORY APPROVAL 195
TABLE 223 PARTNERSHIP 195
TABLE 224 AMGEN INC.: PRODUCTS OFFERED 197
TABLE 225 AMGEN INC.: KEY DEVELOPMENTS 198
TABLE 226 PFIZER INC.: PRODUCTS OFFERED 201
TABLE 227 PFIZER INC.: KEY DEVELOPMENTS 201
TABLE 228 SANDOZ GROUP AG: PRODUCTS OFFERED 204
TABLE 229 SANDOZ GROUP AG: KEY DEVELOPMENTS 205
TABLE 230 NOVARTIS AG: PRODUCTS OFFERED 208
TABLE 231 ELI LILLY AND COMPANY: PRODUCTS OFFERED 211
TABLE 232 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED 214
TABLE 233 ABBVIE, INC.: PRODUCTS OFFERED 217
TABLE 234 RADIUS HEALTH, INC.: PRODUCTS OFFERED 220
TABLE 235 RADIUS HEALTH, INC.: KEY DEVELOPMENT 220
TABLE 236 CIPLA: PRODUCTS OFFERED 225
TABLE 237 ORGANON: PRODUCTS OFFERED 229
TABLE 238 ORGANON: KEY DEVELOPMENT 229